CMOPF Stock - Cosmo Pharmaceuticals N.V.
Unlock GoAI Insights for CMOPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $266.79M | $92.78M | $102.09M | $65.07M | $60.95M |
| Gross Profit | $246.92M | $53.44M | $83.33M | $49.93M | $50.51M |
| Gross Margin | 92.6% | 57.6% | 81.6% | 76.7% | 82.9% |
| Operating Income | $148.88M | $6.15M | $28.06M | $11.10M | $6.91M |
| Net Income | $133.24M | $-4,932,000 | $17.23M | $21.67M | $-7,901,000 |
| Net Margin | 49.9% | -5.3% | 16.9% | 33.3% | -13.0% |
| EPS | $8.15 | $-0.31 | $1.05 | $1.29 | $-0.55 |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Visit WebsiteEarnings History & Surprises
CMOPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 23, 2025 | — | $-0.15 | — | — |
Q1 2025 | Mar 6, 2025 | — | $3.61 | — | — |
Q3 2024 | Jul 24, 2024 | — | $5.06 | — | — |
Q2 2024 | May 24, 2024 | — | $-0.44 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.10 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.62 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.50 | — | — |
Q4 2021 | Dec 31, 2021 | — | $1.60 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.47 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.41 | — | — |
Q2 2020 | Jun 30, 2020 | $-1.00 | $-0.23 | +76.7% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | $-0.38 | $-0.29 | +24.2% | ✓ BEAT |
Q2 2019 | Jun 30, 2019 | — | $-1.60 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.82 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.60 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-1.18 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-1.35 | — | — |
Q4 2016 | Dec 31, 2016 | — | $1.02 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.43 | — | — |
Q4 2015 | Dec 31, 2015 | — | $0.81 | — | — |
Latest News
Frequently Asked Questions about CMOPF
What is CMOPF's current stock price?
What is the analyst price target for CMOPF?
What sector is Cosmo Pharmaceuticals N.V. in?
What is CMOPF's market cap?
Does CMOPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CMOPF for comparison